Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMA‐compliant systematic review—An EAACI position paper
- 3 January 2020
- Vol. 75 (5), 1069-1098
- https://doi.org/10.1111/all.14174
Abstract
Drug hypersensitivity reactions (DHRs) are associated with high global morbidity and mortality. Cutaneous T cell‐mediated reactions classically occur more than 6 hours after drug administration and include life‐threatening conditions such as toxic epidermal necrolysis, Stevens‐Johnson syndrome, and hypersensitivity syndrome. Over the last 20 years, significant advances have been made in our understanding of the pathogenesis of DHRs with the identification of human leukocyte antigens as predisposing factors. This has led to the development of pharmacogenetic screening tests, such as HLA‐B*57:01 in abacavir therapy, which has successfully reduced the incidence of abacavir hypersensitivity reactions. We have completed a PRISMA‐compliant systematic review to identify genetic associations that have been reported in DHRs. In total, 105 studies (5554 cases and 123,548 controls) have been included in the review reporting genetic associations with carbamazepine (n=31), other aromatic antiepileptic drugs (n=24), abacavir (n=11), nevirapine (n=14), trimethoprim‐sulfamethoxazole (n=11), dapsone (n=4), allopurinol (n=10), and other drugs (n=5). The most commonly reported genetic variants associated with DHRs are located in human leukocyte antigen genes and genes involved in drug metabolism pathways. Increasing our understanding of genetic variants that contribute to DHRs will allow us to improve diagnosis, develop new treatments, and predict and prevent DHRs in the future.Keywords
This publication has 143 references indexed in Scilit:
- The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a Northern Han Chinese populationBMC Neurology, 2013
- Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected PopulationClinical Infectious Diseases, 2013
- Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivityPharmacogenetics and Genomics, 2012
- Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentAIDS, 2011
- HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in EuropeansNew England Journal of Medicine, 2011
- Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in EuropeOrphanet Journal of Rare Diseases, 2011
- HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patientsAIDS Research and Therapy, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactionsPharmacogenetics and Genomics, 2006
- Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studiesNature Genetics, 2006